Characteristic | No recurrence (n = 961,809) | Recurrence PTB | |||
---|---|---|---|---|---|
Primary onset (n = 7143) | Recurrence 1 (n = 6739) | Recurrence 2 (n = 379) | Recurrence ≥ 3 (n = 25) | ||
Sex | |||||
Male | 676,648 (70.4) | 5505 (77.1) | 5505 (77.2) | 313 (77.8) | 18 (72.0) |
Female | 285,161 (29.6) | 1638 (22.9) | 1638 (22.8) | 91 (22.2) | 9 (28.0) |
Median (IQR) | 48 (28–63) | 54 (40–64) | 57 (42–67) | 59 (48–68) | 63 (54–68) |
Age group (years) | |||||
0–14 | 9407 (1.0) | 22 (0.3) | 5 (0.1) | 0 (0.0) | 0 (0.0) |
15–29 | 246,098 (25.6) | 1198 (16.8) | 993 (14.7) | 35 (9.2) | 3 (12.0) |
30–44 | 180,552 (18.8) | 1065 (14.9) | 912 (13.5) | 39 (10.3) | 0 (0.0) |
45–59 | 218,838 (22.8) | 2150 (30.1) | 1819 (27.0) | 118 (31.1) | 7 (28.0) |
≥ 60 | 306,504 (31.9) | 2708 (37.9) | 3010 (44.7) | 187 (49.3) | 15 (60.0) |
Unknown | 410 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Median of time delay (days, range) | |||||
Time from onset to first hospital visit | 13 (2–30) | 11 (1–31) | 11 (1–30) | 12 (1–31) | 2 (0–16) |
Time from onset to confirm | 23 (10–40) | 14 (30–59) | 27 (14–44) | 31 (16–50) | 28 (17–36) |
Time from onset to course end | 208 (192–234) | 215 (198–249) | 223 (200–274) | 240 (203–284) | 220 (207–255) |
Time from hospitalization to course end | 185 (182–198) | 189 (184–215) | 199 (183–249) | 210 (184–258) | 211 (191–246) |
Management mode | |||||
Enhanced supervision | 479,607 (49.9) | 3624 (50.7) | 3733 (55.4) | 198 (52.2) | 11 (44.0) |
DOTS | 450,977 (46.9) | 3511 (49.2) | 2922 (43.4) | 175 (46.2) | 13 (52.0) |
Self-medication | 8119 (0.8) | 7 (0.1) | 12 (0.2) | 3 (0.8) | 1 (4.0) |
Unknown | 23,106 (2.4) | 1 (0.0) | 72 (1.1) | 3 (0.8) | 0 (0.0) |
Outcome | |||||
Cured | 292,466 (30.4) | 3212 (45.0) | 1749 (26.0) | 85 (22.4) | 5 (20.0) |
Treatment completed | 483,794 (50.3) | 3931 (55.0) | 3783 (56.1) | 208 (54.9) | 15 (60.0) |
Death | 8112 (0.8) | 0 (0.0) | 92 (1.4) | 7 (1.9) | 1 (4.0) |
Unknown | 177,437 (18.4) | 0 (0.0) | 1115 (16.6) | 79 (20.8) | 4 (16.0) |